Tiziana Life Sciences Ltd (TLSA) - Net Assets
Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has net assets worth $52.00K USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.49 Million) and total liabilities ($11.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TLSA strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.00K |
| % of Total Assets | 0.45% |
| Annual Growth Rate | -13.03% |
| 5-Year Change | -99.87% |
| 10-Year Change | -98.43% |
| Growth Volatility | 246.07 |
Tiziana Life Sciences Ltd - Net Assets Trend (1998–2025)
This chart illustrates how Tiziana Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Tiziana Life Sciences Ltd stock valuation.
Annual Net Assets for Tiziana Life Sciences Ltd (1998–2025)
The table below shows the annual net assets of Tiziana Life Sciences Ltd from 1998 to 2025. Also explore TLSA shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $52.00K | -98.68% |
| 2024-12-31 | $3.94 Million | -28.90% |
| 2023-12-31 | $5.54 Million | -71.71% |
| 2022-12-31 | $19.57 Million | -52.59% |
| 2021-12-31 | $41.28 Million | -33.83% |
| 2020-12-31 | $62.39 Million | +1592.49% |
| 2019-12-31 | $-4.18 Million | -1121.97% |
| 2018-12-31 | $409.01K | +124.30% |
| 2017-12-31 | $-1.68 Million | -150.78% |
| 2016-12-31 | $3.31 Million | -61.03% |
| 2015-12-31 | $8.50 Million | +378.56% |
| 2014-12-31 | $1.78 Million | +1317.12% |
| 2013-12-31 | $-146.00K | -265.00% |
| 2012-12-31 | $-40.00K | -107.62% |
| 2011-12-31 | $525.00K | -13.08% |
| 2010-12-31 | $604.00K | -50.21% |
| 2009-12-31 | $1.21 Million | -9.48% |
| 2008-12-31 | $1.34 Million | -45.08% |
| 2007-12-31 | $2.44 Million | +0.49% |
| 2006-12-31 | $2.43 Million | -14.05% |
| 2005-12-31 | $2.83 Million | -20.27% |
| 2004-12-31 | $3.54 Million | +17.05% |
| 2003-12-31 | $3.03 Million | +37.28% |
| 2002-12-31 | $2.21 Million | -25.56% |
| 2001-12-31 | $2.96 Million | -26.08% |
| 2000-12-31 | $4.01 Million | +101.97% |
| 1999-12-31 | $1.98 Million | -11.94% |
| 1998-12-31 | $2.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tiziana Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4414000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $121.00K | 232.69% |
| Other Comprehensive Income | $9.68 Million | 18615.38% |
| Other Components | $34.66 Million | 66659.62% |
| Total Equity | $52.00K | 100.00% |
Tiziana Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Tiziana Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bonny Worldwide Ltd
TW:8467
|
$133.66 Million |
|
Parkit Enterprise Inc
V:PKT
|
$133.72 Million |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
$133.76 Million |
|
Rawlplug S.A.
WAR:RWL
|
$133.78 Million |
|
MEDIFAST INC
NYSE:MED
|
$133.61 Million |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
$133.61 Million |
|
Inclusio Sca
BR:INCLU
|
$133.60 Million |
|
Smartbroker Holding AG
XETRA:SB1
|
$133.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tiziana Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,936,000 to 52,000, a change of -3,884,000 (-98.7%).
- Net loss of 18,431,000 reduced equity.
- Other comprehensive income decreased equity by 107,310,000.
- Other factors increased equity by 121,857,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.43 Million | -35444.23% |
| Other Comprehensive Income | $-107.31 Million | -206365.38% |
| Other Changes | $121.86 Million | +234340.38% |
| Total Change | $- | -98.68% |
Book Value vs Market Value Analysis
This analysis compares Tiziana Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1194.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 1194.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $2627.04 | $1.05 | x |
| 1999-12-31 | $2391.57 | $1.05 | x |
| 2000-12-31 | $4892.55 | $1.05 | x |
| 2001-12-31 | $2829.04 | $1.05 | x |
| 2002-12-31 | $957.86 | $1.05 | x |
| 2003-12-31 | $647.07 | $1.05 | x |
| 2004-12-31 | $640.34 | $1.05 | x |
| 2005-12-31 | $346.50 | $1.05 | x |
| 2006-12-31 | $191.35 | $1.05 | x |
| 2007-12-31 | $138.10 | $1.05 | x |
| 2008-12-31 | $40.96 | $1.05 | x |
| 2009-12-31 | $11.71 | $1.05 | x |
| 2010-12-31 | $1.72 | $1.05 | x |
| 2011-12-31 | $0.80 | $1.05 | x |
| 2012-12-31 | $-0.04 | $1.05 | x |
| 2013-12-31 | $-0.01 | $1.05 | x |
| 2014-12-31 | $0.31 | $1.05 | x |
| 2015-12-31 | $0.18 | $1.05 | x |
| 2016-12-31 | $0.06 | $1.05 | x |
| 2017-12-31 | $-0.03 | $1.05 | x |
| 2018-12-31 | $0.01 | $1.05 | x |
| 2019-12-31 | $-0.06 | $1.05 | x |
| 2020-12-31 | $0.94 | $1.05 | x |
| 2021-12-31 | $0.84 | $1.05 | x |
| 2022-12-31 | $0.39 | $1.05 | x |
| 2023-12-31 | $0.11 | $1.05 | x |
| 2024-12-31 | $0.07 | $1.05 | x |
| 2025-12-31 | $0.00 | $1.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tiziana Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35444.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 221.06x
- Recent ROE (-35444.23%) is below the historical average (-1435.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -12.07% | 0.00% | 0.00x | 1.19x | $-497.40K |
| 1999 | -27.91% | 0.00% | 0.00x | 1.18x | $-752.50K |
| 2000 | -56.60% | 0.00% | 0.00x | 1.12x | $-2.67 Million |
| 2001 | -78.49% | 0.00% | 0.00x | 1.12x | $-2.62 Million |
| 2002 | -104.58% | 0.00% | 0.00x | 1.16x | $-2.53 Million |
| 2003 | -64.82% | 0.00% | 0.00x | 1.09x | $-2.26 Million |
| 2004 | -39.18% | -1402.02% | 0.02x | 1.17x | $-1.74 Million |
| 2005 | -75.79% | -1845.69% | 0.03x | 1.22x | $-2.42 Million |
| 2006 | -89.62% | -537.28% | 0.13x | 1.30x | $-2.42 Million |
| 2007 | -99.06% | -3776.56% | 0.02x | 1.19x | $-2.66 Million |
| 2008 | -106.64% | -1553.26% | 0.05x | 1.48x | $-1.56 Million |
| 2009 | -60.18% | -1303.57% | 0.03x | 1.43x | $-851.30K |
| 2010 | -774.51% | 0.00% | 0.00x | 1.69x | $-4.74 Million |
| 2011 | -230.08% | 0.00% | -0.20x | 1.19x | $-1.26 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-844.00K |
| 2013 | 0.00% | -9333.33% | 0.02x | 0.00x | $-265.40K |
| 2014 | -197.52% | 0.00% | 0.00x | 1.38x | $-3.69 Million |
| 2015 | -150.38% | 0.00% | 0.00x | 1.09x | $-13.64 Million |
| 2016 | -217.50% | 0.00% | 0.00x | 1.52x | $-7.54 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.60 Million |
| 2018 | -1540.08% | 0.00% | 0.00x | 13.33x | $-6.34 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.89 Million |
| 2020 | -57.17% | 0.00% | 0.00x | 1.55x | $-30.70 Million |
| 2021 | -56.73% | 0.00% | 0.00x | 1.18x | $-27.55 Million |
| 2022 | -78.67% | 0.00% | 0.00x | 1.35x | $-17.35 Million |
| 2023 | -319.56% | 0.00% | 0.00x | 2.20x | $-18.24 Million |
| 2024 | -301.40% | 0.00% | 0.00x | 2.87x | $-12.26 Million |
| 2025 | -35444.23% | 0.00% | 0.00x | 221.06x | $-18.44 Million |
Industry Comparison
This section compares Tiziana Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $219,658,634
- Average return on equity (ROE) among peers: -31.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $52.00K | -12.07% | 220.06x | $133.62 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $121.06 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $316.23 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $960.81 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.21 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $4.38 Billion |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more